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Structured Abstract (Word count- 250) 
Objective: To assess the impact of smoking on short (30 day) and intermediate (30-day 
to 6-month) mortality following PCI.  
Background: Effect of smoking on mortality post-PCI is lacking in the modern PCI era. 
Methods: Retrospective analysis of prospectively collected data comparing short and 
intermediate term mortality amongst smokers, ex-smokers and non-smokers.  
Results: The study cohort consisted of 12,656 patients: never-smokers (n=4288), ex-
smokers (n=4806) and current smokers (n=3562). Mean age (±SD) was 57(±11) years in 
current smokers compared to 67(±11) in ex-smokers and 67 (±12) in never-smokers; P 
< 0.0001. PCI was performed for ACS in 84.1% of current smokers, 57% of ex-smokers 
and 62.9% in never-smokers; P < 0.0001. In a logistic regression model correct, the ad-
justed odds ratios (95% confidence intervals [CI]) for 30-day mortality were 1.60 (1.10 - 
2.32) in current smokers and 0.98 (0.70 - 1.38) in ex-smokers compared to never-smok-
ers. In the Cox proportional hazard model, the adjusted hazard ratios (95% CI) for mor-
tality between 30 days and 6 months were 1.03 (0.65 - 1.65) in current smokers and 1.19 
(0.84 - 1.67) in ex-smokers compared to never-smokers.  
Conclusion: This large observational study of non-selected patients demonstrates that 
ex-smokers and never-smokers are of similar age at first presentation to PCI, and there 
is no short and intermediate term mortality difference between them following PCI.  
Current smokers undergo PCI at younger age, more often for ACS, and have higher 
short-term mortality. These findings underscore the public message on benefits of 
smoking cessation and harmful effects of smoking. 
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Main text - word count 3981 (main text, tables, figures and references) 
 
Smoking Status and Mortality Outcomes Following 
Percutaneous Coronary Intervention 
Introduction 
Smoking is a major risk factor for cardiovascular disease and sudden cardiac death 1, 2, 
with the benefits of quitting well-documented 3.  
Prior studies have confirmed that smokers have reduced life expectancy compared to 
non-smokers 4.  However, data from the pre-thrombolytic, thrombolytic, and early per-
cutaneous coronary intervention (PCI) eras have yielded conflicting results on the sur-
vival of smokers following myocardial infarction 5-7.  Such data are lacking in the mod-
ern PCI era; with advances in PCI technology, new anti-platelet therapy and widespread 
use of secondary prevention, which may differentially influence survival in smokers 
versus non-smokers.  
The aim of this study is to compare the short and intermediate-term mortality of smok-
ers and ex-smokers versus never-smokers following PCI. 
 
Methods 
Study Population: 
The study population consisted of all patients undergoing PCI between March 2008 and 
December 2011 at two regional cardiac centres in the UK - Freeman Hospital, Newcas-
tle-upon-Tyne, and Aberdeen Royal Infirmary, Aberdeen.   
Study Design: 
This was a retrospective analysis of prospectively collected data on all PCI procedures 
during the study period. The primary sources of data were the local Coronary Artery 
Disease (CAD) databases, which hold information on every PCI procedure performed at 
each centre. Baseline demographics, procedure details, and clinical data were prospec-
tively entered into these databases at the time of the procedure and updated on dis-
charge.  
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Outcome Measures: 
The main outcome measure was all-cause mortality assessed at 30 days (30-day mortal-
ity) and between 30 days and 6-months (intermediate-term mortality) post PCI. Mortal-
ity data were provided by the Office of National Statistics (ONS) and Grampian Health 
Intelligence and were linked to our databases using National Health Service (NHS) or 
Community Health Identifier (CHI) patient-unique identification numbers. Mortality 
was assessed up to the 2nd February 2012, and patient follow-up was censored upon 
death. 
Smoking Status and Procedure Setting:  
Patients were classified into three groups according to their smoking status at time of 
index PCI: 1) “Never smokers” have never smoked cigarettes; 2) “Ex-smokers” stopped 
smoking at any point prior to their index PCI procedure; and 3) “Current smokers” con-
tinued to smoke. These definitions were used by cardiologists, who collected and rec-
orded the history and performed PCI.  
PCI was classified according to the clinical setting: ‘elective’ PCI for patients presenting 
with stable coronary artery disease (CAD) and ‘acute’ PCI for patients with acute coro-
nary syndrome (unstable angina, non-ST elevation and ST elevation myocardial infarc-
tion).  
All patients presenting with acute coronary syndrome were seen by the cardiac rehabil-
itation team during their hospital stay or contacted soon following their discharge and 
offered a referral to smoking cessation services. Elective patients were advised regard-
ing smoking and offered a referral to smoking cessation team at the time of their cardi-
ology clinic visit or by their general practitioners.  
Statistical analysis: 
Data are presented as percentages for categorical variables and as means ± standard de-
viations (SD) or medians and interquartile ranges (25th to 75th) for continuous varia-
bles. Comparisons between groups were made using chi-squared test for categorical 
variables and one-way ANOVA for continuous variables. Multiple logistic regression 
analysis was used to test for the impact of smoking on 30-day mortality and to correct 
for confounders. For the longitudinal analysis for intermediate-term mortality, Kaplan-
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Meier survival curves were generated, and the log-rank test was used to assess for dif-
ferences in survival. Cox proportional hazards regression was used to assess the impact 
of smoking status on intermediate-term mortality following adjustment for confound-
ers. P value <0.05 (2-sided) was considered statistically significant. All analysis was per-
formed using SPSS (SPSS version 19, SPSS, Inc., Chicago).    
 
Results 
A total of 13041 patients underwent PCI during the study period. Data on smoking sta-
tus were missing in 385 patients. The remaining 12656 patients were included in this 
analysis and their smoking status was recorded as follows: never-smokers (n=4288, 
33.9%), ex-smokers (n=4806, 38.0%) and current smokers (n=3562, 28.1%).  
Baseline characteristics are detailed in Table 1.  
 
Table 1: Baseline patient characteristics 
Abbreviations: SD-Standard Deviation; MI-Myocardial Infarction; CVA-Cerebro-Vascular 
Accident; TIA-Transient Ischemic Attack; PVD-Peripheral Vascular Disease;  
 
 
Current smokers were 10 years younger compared to other groups (p<0.001), while 
never-smokers and ex-smokers were of similar age. The never- and ex-smoker cohorts 
were more likely to have suffered a previous myocardial infarction (MI), cerebro-vascu-
lar accident (CVA) and to have undergone previous PCI compared to the current smoker 
group. Current smokers were less likely to have pre-existing hypertension and/or dia-
betes compared to other groups. Peripheral vascular disease (PVD) and airway disease 
were more prevalent in current and ex-smokers compared to never-smokers, Table 
1.The percentage of patients undergoing PCI for ACS was highest in current smokers 
(84.1%) compared to ex-smokers (57.0%) and never-smokers (62.9%); P < 0.0001 (ta-
ble 2). Among smokers, 30% had multi vessel disease and 1.3% had left main stem dis-
ease compared to 37.5% and 2.6% for ex-smokers and 36.3% and 2.0% for the never-
smokers, respectively.  
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Table 2: Indication for PCI 
Abbreviations: ACS-Acute coronary syndrome 
 
 
After excluding patients with any previous coronary revascularisation (PCI or CABG) 
and analysing only those in whom the study index PCI procedure was their first ever 
coronary revascularisation (n=10612), current smokers were still significantly younger 
and more likely to have PCI for ACS compared to other groups, Table 3. 
 
Table 3: First presentation for PCI 
Abbreviations: PCI-Percutaneous Coronary Intervention; ACS-Acute Coronary Syn-
drome 
 
 
At discharge, 94.8% of patients were on dual anti-platelet therapy, 94.6% on a statin, 
84.8% on a beta blocker and 84.9% on an angiotensin converting enzyme inhibitor or 
an angiotensin receptor blocker.  
 
Thirty-day mortality outcome: 
Overall 30-day mortality rate was 1.8%. The respective figures in the never-smokers, 
ex-smokers and current smokers groups were 1.7%, 1.7% and 1.9%. In a logistic regres-
sion model corrected for Age, gender, PCI setting, diabetes, airway disease, history of 
previous MI, history of other vascular disease and the presence of left main stem/multi-
vessel disease, the adjusted odds ratios (95% confidence intervals [CI]) for 30-day mor-
tality were 0.98 (0.70 - 1.38) in ex-smokers and 1.60 (1.10 - 2.32) in current smokers 
compared to never-smokers. See table 4, Figure 1. 
 
Figure 1: Thirty-day mortality among the three groups- the adjusted odds ratios 
(95% confidence intervals [CI]) for 30-day mortality were 0.98 (0.70 - 1.38) in ex-
smokers and 1.60 (1.10 - 2.32) in current smokers compared to never-smokers 
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Table 4: Crude and adjusted mortality among the groups 
 
Abbreviations: CI- Confidence Interval 
 
 
Six-month mortality outcome: 
Overall 30-day to 6-month mortality rate was 1.5%. In the Cox proportional hazard 
model adjusted for age, gender, PCI setting, diabetes, airway disease, history of previous 
MI, history of other vascular disease and the presence of left main stem/multi-vessel 
disease the adjusted hazard ratios (95% CI) for mortality between 30 days and 6 
months were 1.03 (0.65 - 1.65) in current smokers and 1.19 (0.84 - 1.67) in ex-smokers 
compared to never-smokers (Figure 2). 
 
Figure 2: 30-day to 6-month mortality among the three groups- the adjusted hazard 
ratios (95% CI) for mortality between 30 days and 6 months were 1.03 (0.65 - 1.65) 
in current smokers and 1.19 (0.84 - 1.67) in ex-smokers compared to never-smokers 
 
Discussion 
There are three main findings from this large observational study of unselected, all-
comers PCI cohort. Firstly, smokers undergo PCI at a much younger age and more fre-
quently for an ACS presentation. Secondly, smoking is associated with a higher 30-day 
mortality compared to never-smokers. Thirdly, ex-smokers have similar presentation 
age for PCI and mortality outcomes to never-smokers. To our knowledge, this is the first 
study to demonstrate such favourable findings in ex-smokers compared to current 
smokers in the modern PCI era.  
Smoking is a risk factor for coronary thrombosis and myocardial infarction 8. The risk of 
acute myocardial infarction in young smokers is almost three times that of never-smok-
ers and it diminishes to baseline if they quit smoking for more than two years 9. There is 
also a clear dose response relationship between smoking and cardiovascular risk with 
no safe lower limit 10. 
In our study, smokers underwent PCI at a considerably younger age (10 years younger) 
compared to ex- and never-smokers; despite having the lowest rates of other cardiovas-
cular risk factors such as hypertension and diabetes. A similar observation was noted in 
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previous observational studies from different eras and across different ACS presenta-
tions 11, 12. This confirms the impact of smoking as a major risk factor for coronary ar-
tery disease. In our study, the age difference remained equally significant even when we 
only looked at patients in whom the index PCI procedure was their first ever coronary 
revascularisation. Interestingly, there was no age difference between never- and ex-
smokers. From a public health point of view, the message from this study is that smok-
ers presented with accelerated coronary artery disease and intrusive symptoms at a 
younger age and importantly quitting smoking eliminates this age difference at first 
presentation. 
When looking at gender differences, women appear to be more prone to the deleterious 
effects of smoking with female smokers having higher risk of developing acute myocar-
dial infarction compared to male smokers 13. It has been shown that women metabolise 
nicotine faster due to oestrogen 14, which may explain their higher risk.   
In our study, smokers had PCI more commonly for acute coronary syndromes compared 
to never-smokers and ex-smokers. Studies have shown that smokers have endothelial 
dysfunction 15 and higher platelet aggregability 16. Newby et al demonstrated impair-
ment of smokers’ endothelium to release tissue-plasminogen activator, probably caus-
ing impaired endogenous fibrinolysis 17. As a result, otherwise subclinical micro-throm-
bus could propagate to an occlusive thrombus. Furthermore, denudation of endothe-
lium and micro-thrombi are common on the surface of atheromatous plaques 18 and the 
fact that smokers benefit from dual anti-platelet therapy significantly more than never-
smokers is suggestive of  an altered rheology among smokers 19.  Burke et al demon-
strated that among men who suffered sudden cardiac death due to acute thrombosis, 
75% were smokers 20. He further showed that  in women suffering sudden cardiac 
death, smoking was a risk factor for both plaque erosion and rupture 21. Smoking causes 
endothelial injury, atherogenesis, inflammation and impaired vasomotor function, all of 
which predispose to atheromatous plaque formation 22, 23.  
Our study highlights some angiographic differences between groups including higher 
prevalence of multi-vessel and left main stem disease among ex- and never-smokers 
compared to smokers. This observation closely resembles the data from TRANSFER-
AMI trail 24. A higher prevalence of acute presentation despite relatively mild underly-
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ing coronary disease further supports the hypothesis that smoking expedites plaque in-
stability, and in some cases leads to thrombus formation and/or impaired endogenous 
thrombolysis. 
Surprisingly, studies from the pre-thrombolytic, thrombolytic and old PCI eras sug-
gested a similar or even better survival among smokers compared to never-smokers 
post myocardial infarction 5-7. Barbash et al found never smoking to be associated with 
an increased in-hospital complication rates and early mortality post thrombolysis even 
after correcting for differences in baseline clinical characteristics 6. The TIMI-II study 
showed that the risk of death and  fatal and non-fatal MI at 42 days was highest among 
never smokers 25. This conundrum was termed the “smoker’s paradox”, although no 
plausible mechanistic explanation has ever been postulated 11.  
The ACUITY trial showed smoking to be an independent risk factor for 1-year mortality 
in patients presenting with non-ST elevation acute coronary syndrome patients 11. The 
life expectancy after AMI was less among elderly (≥65) smokers than never-smokers, 
leading to  significant loss of life years 26. In those with coronary artery disease, smoking 
cessation has been shown to reduce mortality irrespective of age, sex, index cardiac 
event or nationality27, 28.  Hasdai et al followed up 5,450 patients undergoing PCI at 
Mayo clinic between 1979 and 1995 over a mean of 4.5 years 7. The crude mortality was 
lower in smokers but the mortality adjusted for baseline variables was higher in smok-
ers than never-smokers, ex-smokers and quitters. In addition, the adjusted risk for need 
for future revascularisation was lower in the smoking group. It has been shown that 
younger patients with ST-elevation myocardial infarction (STEMI) treated by primary 
PCI have a better survival than older patients (>45 years), likely due to differences in 
baseline comorbidities 29. It is probable that younger age and associated favourable pro-
file are to be credited for better outcomes among smokers in some past studies.  
There has been considerable advancement in the management of patients undergoing 
PCI. The use of secondary prevention and dual antiplatelet therapy is now well-estab-
lished in this population and newer antiplatelet agents  30, 31 have also contributed to 
improved post PCI outcomes. As a result, there has been significant reduction in cardio-
vascular deaths driven by a reduction in fatal myocardial infarction and sudden cardiac 
death in patients undergoing PCI 32.  Our study population was a well-treated cohort, 
with high use of dual anti-platelet therapy, statins and other cardiovascular drugs.  
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In our study, 30-day mortality among smokers was higher, despite a significantly 
younger age and better clinical profile at presentation. Meanwhile, 30-day to 6-month 
mortality rates were similar in the three groups. We obtained only a snapshot smoking 
history at the time of presentation to PCI but no data for subsequent smoking habits 
were recorded. Hence, we believed a focus on short mortality will be a true reflection of 
the effects of smoking in our cohort.  Furthermore, the deleterious effect of smoking on 
endothelial function and thrombosis in patients undergoing PCI is most likely to have 
the biggest impact on short term outcomes; particularly given the high cardiovascular 
event rate in this period. Importantly, ex-smokers exhibited no difference in either 
short or intermediate term mortality compared to never-smokers. The inference from 
this is that giving up smoking can reduce the risk of death after PCI to never-smokers’ 
levels.  
Primary care-based health checks have been shown to improve the management of car-
diovascular risk factors such as hypertension, hypercholesterolemia and high body 
mass index 33.  However, smokers are less likely to participate in such health checks 34, 
which underscores the complex interaction between cardiovascular risk factors and 
preventative strategies.   
Increasing public awareness, government policies, media campaigns and counselling 
have resulted in a positive trend in smoking cessation.  In the United States, the preva-
lence of smoking among adults has decreased from 42.4% to 19.3% from 1965 to 2010 
and the number of ex-smokers exceeding that of current smokers in 2002  35.  Further-
more, in Scotland, Finland and Switzerland, prohibition of smoking in public indoor 
spaces has led to significant reduction in hospital admissions with acute coronary syn-
drome 36-38.  
Limitation and strength: 
Data on smoking intensity and duration of smoking cessation in ex-smokers were not 
collected. We also did not collect data on the proportion of patients who attended car-
diac rehabilitation or smoking cessation services and no follow-up on the smoking sta-
tus was made. Consequently, only short term and intermediate term mortality data 
were analysed. Nevertheless, the current study examines post PCI outcomes in a large 
cohort.  
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Conclusion 
This large observational study of unselected patients treated with PCI in the modern era 
demonstrates that smokers undergo PCI at a much younger age and more commonly for 
acute coronary syndrome compared to never-smokers. In addition, current smoking 
was associated with increased 30-day mortality. This age difference and survival disad-
vantage was not seen in ex-smokers. Our findings reinforce the public message of the 
harmful effect of smoking and the benefits of smoking cessation. 
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Table 1: Baseline patient characteristics 
Descriptive 
12656 
Never-
smokers 
4288 
(32.9%) 
Ex-smokers 
4806 
(36.9%) 
Current 
smokers 
3562 
(27.3%) 
Significance 
Age 
(mean ± SD) 
years 
67±12  67±11  57±11  P<0.001 
 
Male gender (72.3%) 
 
67.1% 
 
77% 
 
72.2% 
 P<0.001 
Hypertension 
49.6% 
50.5% 57.2% 38.3% P<0.001  
Hypercholesterolemia 
33.9% 
32.6% 35.1% 34% P=0.043  
Diabetes 
16.9% 
17.7% 20% 11.7% P<0.001 
Previous MI 
22.9% 
19% 30.2% 17.8% P<0.001  
Previous coronary revas-
cularisation 
14.5% 22.3% 9.8% P<0.001 
CVA/TIA 
5.7% 
5.4% 6.6% 4.7% P=0.001 
Family History 
44.2% 
37.3% 47.1% 48.7% P<0.001  
Peripheral vascular dis-
ease 4.9% 
2.8% 6.9% 4.6%  P<0.001 
Airway disease 
11.4% 
7.2% 14.6% 12.2%  P<0.001  
 
 
Abbreviations: SD-Standard Deviation; MI-Myocardial Infarction; CVA-Cerebro-Vascular 
Accident; TIA-Transient Ischemic Attack; PVD-Peripheral Vascular Disease 
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Table 2: Indication for PCI 
Descriptive Non-smokers Ex-smokers Current smokers Significance 
Elective 
(33.7) 
 
(37.1) 
(43) (15.9) p<0.001 
ACS 
(66.7) 
(62.9)  (57)  (84.1) p<0.001 
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Table 3: First presentation for PCI 
 
Never-
smokers 
Ex-smokers 
Current 
smokers 
P-value 
Elective, % 
          Mean age ± SD, years 
35 
67±12 
39.3 
68±11 
14.1 
57±11 
< 0.001 
< 0.001 
ACS, % 
          Mean age ± SD, years 
65 
66±11 
60.7 
66±9 
85.9 
58±10 
< 0.001 
< 0.001 
 
Abbreviations: PCI-Percutaneous Coronary Intervention; ACS-Acute Coronary Syn-
drome 
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Table 4: Crude and adjusted mortality among the groups 
 
 
 Crude 30-day 
mortality 
n (%) 
Adjusted 30-day 
mortality 
odds ratio  
(95% CI) 
Crude 30 day 
to 6-month 
mortality 
n (%) 
Adjusted 30 day 
to 6-month mor-
tality 
Hazard ratio 
(95% CI) 
Non-smokers 
(n=4288) 
74 (1.7) 1.00    64 (1.5) 1.00 
Ex-smokers 
(n=4807) 
82 (1.7) 0.98 (0.7-1.38) 91 (1.9) 1.19 (0.84-1.67) 
Current Smokers 
(n=3563) 
68 (1.9) 1.60 (1.1-2.32) 32 (0.9) 1.03 (0.65-1.65) 
 
Abbreviations: CI- Confidence Interval 
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Figure 1: Thirty-day mortality among the three groups- the adjusted odds ratios (95% 
confidence intervals [CI]) for 30-day mortality were 0.98 (0.70 - 1.38) in ex-smokers 
and 1.60 (1.10 - 2.32) in current smokers compared to never-smokers 
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Figure 2: 30-day to 6-month mortality among the three groups- the adjusted hazard ra-
tios (95% CI) for mortality between 30 days and 6 months were 1.03 (0.65 - 1.65) in 
current smokers and 1.19 (0.84 - 1.67) in ex-smokers compared to never-smokers 
 
 
 
 
 
 
 
